An exploratory analysis of the NeoALTTO trial reported lower pCR rates in overweight and obese patients with hormone-positive and Her2+ breast cancer, compared to underweight and lean patients, whereas this trend was not observed in patients with hormone-negative and Her2+ breast cancer [29]. This evidence concerns the gene ERBB2 and breast cancer.